Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324314 | PMC |
| http://dx.doi.org/10.1016/j.jvir.2020.06.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation between transforming growth factor-β1 (TGF- β1) with premature atherosclerosis in type 1 diabetes.
ARYA Atheroscler
January 2024
Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
Background: Type 1 diabetes (T1D) carries a significant risk of atherosclerosis as the main driver for cardiovascular events. Atherosclerosis is initiated by the activation of the endothelium by various risk factors through the inflammation process. The anti-inflammatory cytokine TGF-β1 may inhibit the development of atherosclerosis.
View Article and Find Full Text PDFEvaluating the role of active TGF-β1 as inflammatory biomarker in Kashmiri (North-Indian) patients with systemic sclerosis: a case-control study.
Adv Rheumatol
December 2024
Department of Immunology & Molecular Medicine, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Soura, Srinagar, Jammu and Kashmir, 190011, India.
Background: As a master immune system regulator, transforming growth factor β1 (TGF-β1) is closely linked to the complicated pathophysiology and development of systemic sclerosis (SSc), a multisystem fibrotic disease.
Objective: We aim to evaluate the transcriptional levels of TGF-β1 mRNA in PBMCs, assess the TGF-β1 serum levels of SSc patients, and compare them with those of healthy subjects.
Methods: PBMCs were isolated from whole blood of 50 SSc patients and in 30 healthy controls.
Significance of plasma TGF-β1 level detection in patients with T2DM with heart failure.
J Med Biochem
September 2024
Xingtai Third Hospital, Cardiology Ward 2, Xingtai, China.
Background: The aim of the study was to examine the significance of plasma Transforming Growth Factor-1/TGF-β1 (TGF-β1) level testing in patients with Type 2 Diabetes Mellitus (T2DM) and heart failure.
Methods: A sample of T2DM patients who were hospitalised for dyspnea was chosen between June 2021 and June 2023. Based on the convenience sample approach, 150 cases were screened for the study, and 50 healthy non-diabetic people without cardiac problems who completed physical examinations over the same period were included as a control group.
Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data.
Lancet Microbe
December 2024
Amsterdam University Medical Centres, Amsterdam, Netherlands; Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.
Background: Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the protection against disease would accelerate tuberculosis vaccine development. We aimed to assess whether the effectiveness of the Bacillus Calmette-Guérin (BCG) vaccine for prevention of Mycobacterium tuberculosis infection was consistent with that for prevention of tuberculosis disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!